Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sol-Gel TechnologiesSLGL -2.62%45 Cash-to-Debt is 62.25 as of Jun. 2026, which is 128% above its 10-year median of 27.30. GuruFocus rates SLGL with a GF Score™ of 45/100 and a GF Value™ of $5.95 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,332 Biotechnology companies, Sol-Gel Technologies ranks better than 72.07% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sol-Gel Technologies's cash to debt ratio for the quarter that ended in Jun. 2026 was 62.25.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Sol-Gel Technologiescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Sol-Gel Technologies's Cash-to-Debt or its related term are showing as below:
SLGL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14 Med: 27.3 Max: No Debt
Current: 62.25
During the past 11 years, Sol-Gel Technologies's highest Cash to Debt Ratio was No Debt. The lowest was 0.14. And the median was 27.30.
SLGL's Cash-to-Debt is ranked better than 72.07% of 1332
companies
in the Biotechnology industry
Industry Median: 7.355
vs SLGL: 62.25
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Sol-Gel Technologies Cash-to-Debt Related Terms
Sol-Gel Technologies Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Sol-Gel Technologies's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Sol-Gel Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sol-Gel Technologies Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Sol-Gel Technologies's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sol-Gel Technologies (SLGL) has a Cash-to-Debt of 62.25 as of Jun. 2026. This is 128% above median its historical median of 27.30. Over the past decade, Sol-Gel Technologies' Cash-to-Debt has ranged from 0.14 to 10,000.00. According to the industry distribution chart, Sol-Gel Technologies ranks #372 out of 1332 companies in the Biotechnology industry, placing it in the top 27.9%.
Is Sol-Gel Technologies' Cash-to-Debt too high?
Sol-Gel Technologies' current Cash-to-Debt of 62.25 is 128% above median its 10-year median of 27.30. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.36. Sol-Gel Technologies' value of 62.25 is 746.4% above this industry median. Based on the distribution chart, Sol-Gel Technologies ranks #372 out of 1332 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sol-Gel Technologies has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' Cash-to-Debt compare to SABS and BCYC?
According to the Biotechnology industry distribution chart, Sol-Gel Technologies ranks #372 out of 1332 companies for Cash-to-Debt. This puts Sol-Gel Technologies in the upper half of its industry. The industry median Cash-to-Debt is 7.36. Sol-Gel Technologies' value of 62.25 is 746.4% above this benchmark. Historically, Sol-Gel Technologies' own Cash-to-Debt has ranged from 0.14 to 10,000.00 over the past decade. While the company's 10-year median is 27.30 vs. the industry median of 7.36, Sol-Gel Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.36, based on 1,332 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sol-Gel Technologies's current Cash-to-Debt of 62.25 is 746.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sol-Gel Technologies's current Cash-to-Debt is 62.25, which is 128% above median its own 10-year median of 27.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.95, compared to a current price of $78.38 — trading 1217.3% above its estimated fair value. The current Cash-to-Debt is 62.25, which is 128% above median its 10-year median of 27.30 and 746.4% above the Biotechnology industry median of 7.36. Sol-Gel Technologies' overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current Cash-to-Debt is 62.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sol-Gel Technologies (SLGL) Overvalued in 2026?
Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued.
The current stock price of $78.38 is trading 1217.3% above its estimated GF Value™ of $5.95.
GuruFocus considers Sol-Gel Technologies to be Significantly Overvalued.
Key valuation signals for SLGL:
Cash-to-Debt: 62.25 (128% above median its 10-year median of 27.30)
GF Value™: $5.95 vs. price of $78.38 (1217.3% above fair value)
Industry Position: 746.4% above the Biotechnology median (#372 of 1332)
No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
45GF Score
Get the complete analysis for SLGL
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLGL has been successfully added to your 
